Arcellx, Inc. (ACLX)
| Market Cap | 2.70B |
| Revenue (ttm) | 47.17M |
| Net Income (ttm) | -129.53M |
| Shares Out | 48.67M |
| EPS (ttm) | -2.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 313,819 |
| Open | 57.00 |
| Previous Close | 56.88 |
| Day's Range | 55.26 - 57.07 |
| 52-Week Range | 26.32 - 59.10 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 53.73 (-3.19%) |
| Earnings Date | Nov 13, 2023 |
About ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid le... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for ACLX stock is "Strong Buy." The 12-month stock price forecast is $53.73, which is a decrease of -3.19% from the latest price.
News
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
-- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months – -- The estimated median p...
Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium
Shares of Arcellx Inc. ACLX, +4.33% were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by Gilead Sciences Inc.'s GILD, -0.28% Kite as part of an expand...
Kite and Arcellx Announce Expansion in Strategic Partnership
SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced that the companies have expanded their existing c...
ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
-- Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment -- -- Kite exercises option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma -- -- ...
Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights
-- Recently released ASH abstract for the company's Phase 1 CART-ddBCMA trial demonstrated that median duration of response, progression free survival, and overall survival not reached with median fol...
Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition
-- Abstract released today is from a June 2, 2023 data cut -- -- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA i...
Arcellx to Participate in Two Upcoming Investor Conferences
REDWOOD CITY, Calif. , Oct. 26, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients w...
Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results
-- Company expects to present preliminary data from iMMagine-1 study in 2H'24 -- REDWOOD CITY, Calif. , Aug. 14, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX
NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arcellx, Inc. ("Arcellx" or the "Company") (NASDAQ: ACLX). Such investors are advised to contac...
Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program
-- FDA has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion -- REDWOOD CITY, Calif. , June 19, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX)...
Arcellx Provides First Quarter Financial Results
REDWOOD CITY, Calif. , May 8, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients wit...
Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference
REDWOOD CITY, Calif. , April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients ...
Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
-- Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma -- -- Presented continued robust long-term responses from CART-ddBCMA...
Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference
REDWOOD CITY, Calif. , Feb. 21, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients w...
Arcellx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif. , Feb. 2, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients wi...
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies' previously announ...
Gilead to co-develop Arcellx's multiple myeloma drug
Gilead Sciences Inc. GILD, +1.91% said Friday that it will co-develop and co-commercialize Arcellx Inc.'s ACLX, +7.22% multiple myeloma treatment candidate, which is currently in Phase 2 clinical tria...
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop ...
Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress
-- 100% ORR at both CART-ddBCMA dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 27 of 38 (71%) evaluable patients reached CR/sCR; 20 of 25 patients (80%...
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; ...
Arcellx Reports Third Quarter 2022 Financial Results and Business Progress
-- Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA -- -- Longer-term follow-up patient data from the Phase 1 CART-ddBCMA expansion trial will be presented at the 64th ASH Annual Meeting in...
Arcellx Announces Presentation of New Clinical Data from Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 64th ASH Annual Meeting and Exposition
-- ASH abstract contains previously presented data from June 2022 -- -- New clinical data from a recent data cut will be presented at ASH -- -- Company to host a live webcast event with an expert pane...
Arcellx Announces Participation at the Morgan Stanley 20th Annual Global Healthcare Conference
REDWOOD CITY, Calif. , Sept. 7, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients w...
Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results
-- Completed upsized follow-on offering of common stock, raising $128.8 million in gross proceeds including full exercise of underwriters' option to purchase additional shares -- -- Presented continue...
Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel
REDWOOD CITY, Calif. , June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients w...